From Unknown Unknowns to Known Unknowns
Through Genomics, Lung Cancer Begins to Cough Up its Secrets
By Anette Breindl
Tuesday, September 25, 2012
At the 2011 meeting of the American Society of Clinical Oncology (ASCO), outgoing president George Sledge told the audience that while drug developers were becoming smarter than "stupid cancers" cancers defined and driven largely by a single mutation that could be attacked with targeted therapies they needed to become smarter than "smart cancers" that are characterized by an overall high mutational load and will quickly mutate their way around any targeted therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.